CR20150007A - Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos - Google Patents

Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Info

Publication number
CR20150007A
CR20150007A CR20150007A CR20150007A CR20150007A CR 20150007 A CR20150007 A CR 20150007A CR 20150007 A CR20150007 A CR 20150007A CR 20150007 A CR20150007 A CR 20150007A CR 20150007 A CR20150007 A CR 20150007A
Authority
CR
Costa Rica
Prior art keywords
preparation
methods
well
estra
tetraene
Prior art date
Application number
CR20150007A
Other languages
English (en)
Inventor
Ulrich Bothe
Matthias Busemann
Oliver Martin Fischer
Naomi Barak
Andrea Rotgeri
Tobias Marquardt
Christian Stegmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20150007A publication Critical patent/CR20150007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a inhibidores de AKR1C3 y a métodos para su preparación, su uso para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medica- mentos para el tratamiento y/o la prevención de enfermedades, en especial de trastornos hemorrágicos y endometriosis.
CR20150007A 2012-07-10 2015-01-09 Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos CR20150007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012211970 2012-07-10
PCT/EP2013/064257 WO2014009274A1 (de) 2012-07-10 2013-07-05 3-substituierte estra-1,3,5 (10),16-tetraen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
CR20150007A true CR20150007A (es) 2015-03-13

Family

ID=48748225

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150007A CR20150007A (es) 2012-07-10 2015-01-09 Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Country Status (27)

Country Link
US (1) US9512169B2 (es)
EP (1) EP2872524B1 (es)
JP (1) JP6196302B2 (es)
KR (1) KR20150036319A (es)
CN (1) CN104428309B (es)
AP (1) AP2014008179A0 (es)
AR (1) AR092025A1 (es)
AU (1) AU2013289344A1 (es)
BR (1) BR112015000443A2 (es)
CA (1) CA2878485A1 (es)
CL (1) CL2015000039A1 (es)
CO (1) CO7160008A2 (es)
CR (1) CR20150007A (es)
DO (1) DOP2015000005A (es)
EA (1) EA201500112A1 (es)
EC (1) ECSP15000868A (es)
ES (1) ES2603258T3 (es)
IL (1) IL236581A0 (es)
MA (1) MA37742B1 (es)
MX (1) MX2015000347A (es)
PE (1) PE20150353A1 (es)
PH (1) PH12015500062A1 (es)
TN (1) TN2015000007A1 (es)
TW (1) TW201402596A (es)
UY (1) UY34899A (es)
WO (1) WO2014009274A1 (es)
ZA (1) ZA201500920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2678993T3 (es) * 2013-02-21 2018-08-21 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibición de la 17beta-hidroxiesteroide deshidrogenada (AKR1C3)
EP3194419B1 (en) * 2014-09-11 2018-09-05 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
US20200085791A1 (en) 2016-12-19 2020-03-19 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3555067A1 (en) 2016-12-19 2019-10-23 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132449C (en) * 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
DK0973790T3 (da) 1997-04-07 2003-09-22 Wyeth Corp Estra-5(10),7-diener med østrogen aktivitet
HUP0101809A3 (en) * 1998-03-11 2002-07-29 Endorech Inc Sainte Foy Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
ID28791A (id) * 1998-08-07 2001-07-05 Endorech Inc PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3
JPWO2001081364A1 (ja) * 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−１，３，５（１０）−トリエン誘導体
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
KR20080114711A (ko) 2006-03-02 2008-12-31 아스텔라스세이야쿠 가부시키가이샤 17β ＨＳＤ 타입 5 저해제
AU2007327653B2 (en) 2006-11-30 2013-04-18 Solvay Pharmaceuticals Gmbh Substituted estratrien derivatives as 17beta HSD inhibitors
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
JP5251876B2 (ja) 2007-07-24 2013-07-31 アステラス製薬株式会社 ベンズイミダゾール誘導体
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
AR092025A1 (es) 2015-03-18
MX2015000347A (es) 2015-04-14
EA201500112A1 (ru) 2015-07-30
BR112015000443A2 (pt) 2017-06-27
US20150210734A1 (en) 2015-07-30
CA2878485A1 (en) 2014-01-16
CO7160008A2 (es) 2015-01-15
EP2872524A1 (de) 2015-05-20
DOP2015000005A (es) 2015-02-15
CL2015000039A1 (es) 2015-03-27
PH12015500062A1 (en) 2015-03-02
MA37742A1 (fr) 2016-05-31
US9512169B2 (en) 2016-12-06
TW201402596A (zh) 2014-01-16
CN104428309A (zh) 2015-03-18
ECSP15000868A (es) 2016-01-29
ES2603258T3 (es) 2017-02-24
AU2013289344A1 (en) 2015-02-05
HK1205743A1 (en) 2015-12-24
PE20150353A1 (es) 2015-03-28
MA37742B1 (fr) 2016-12-30
ZA201500920B (en) 2017-01-25
WO2014009274A1 (de) 2014-01-16
UY34899A (es) 2014-02-28
JP2015522050A (ja) 2015-08-03
IL236581A0 (en) 2015-02-26
AP2014008179A0 (en) 2014-12-31
KR20150036319A (ko) 2015-04-07
EP2872524B1 (de) 2016-08-24
JP6196302B2 (ja) 2017-09-13
TN2015000007A1 (en) 2016-06-29
CN104428309B (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
UY35210A (es) Inhibidores de autotaxina
IN2014DN06501A (es)
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
NI201400032A (es) Piridopirazinas anticancerígenas via la
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY31922A (es) Compuestos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
MX2018013701A (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.